Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
January 04 2022 - 4:15PM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced Pablo J. Cagnoni, M.D.,
president and chief executive officer, will present at the virtual
40th Annual J.P. Morgan Healthcare Conference on Wednesday, January
12, 2022, at 8:15 a.m. ET.
A live audio webcast will be available within the Investors
& Media section of the Rubius Therapeutics website. An archived
replay will be accessible for 30 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was recently named among the 2021 Top
Places to Work in Massachusetts by the Boston Globe, and its
manufacturing site was recently named 2021 Best Places to
Work in Rhode Island by Providence Business News. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Contacts:InvestorsElhan Webb,
CFA, VP Investor Relationselhan.webb@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024